arrow_back Trending Legislation
Share share

Kidney Care Improvement: Research, Treatment, and Insurance Access

This act aims to enhance care for individuals with kidney disease. It introduces new screening tests, facilitates access to disease education, and supports innovative therapies. Additionally, it expands access to Medicare supplemental insurance for kidney disease patients, potentially reducing their treatment costs.
Key points
Kidney disease screenings included in annual Medicare wellness visits.
Easier access to kidney disease education, including at dialysis facilities.
Support for new, innovative drugs and technologies in kidney disease treatment.
Study to increase kidney transplantation rates.
Incentives for nephrology professionals to work in underserved areas.
Guaranteed access to Medicare supplemental policies (Medigap) for individuals with end-stage renal disease, regardless of age.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Chronic Kidney Disease Improvement in Research and Treatment Act of 2023
Print number: HR 5027
Sponsor: Rep. Miller, Carol D. [R-WV-1]
Process start date: 2023-07-27
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Kidney Care Improvement: Research, Treatment, and Insurance Access

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 5027.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-07-27.

What are the main provisions?

Key points include:

  • Kidney disease screenings included in annual Medicare wellness visits.
  • Easier access to kidney disease education, including at dialysis facilities.
  • Support for new, innovative drugs and technologies in kidney disease treatment.
  • Study to increase kidney transplantation rates.
  • Incentives for nephrology professionals to work in underserved areas.
  • Guaranteed access to Medicare supplemental policies (Medigap) for individuals with end-stage renal disease, regardless of age.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Miller, Carol D. [R-WV-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Analysis and Potential Impact of HR 5027

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Benefits